Atopic Dermatitis model / Pathology background / Clinical views

Imavita / Atopic Dermatitis

Atopic Dermatitis or atopic eczema is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Though the condition affects people of all ages, it is primarily common among infants and children. Symptomatic treatment of atopic dermatitis relies primarily on the use of topical formulations (corticosteroids and immunosuppressors). Physicians consider current oral treatments to have limited value in the treatment of atopic dermatitis; antihistamines are the primary class of oral agents used. Due to its chronic and relapsing nature, atopic dermatitis presents a global public health concern, with reported lifetime prevalence ranging between 10%-20% in children and 1%-3% in adults.

That’s the reason why preclinical models of Atopic Dermatitis are needed for testing efficacy prior to clinical testing.
IMAVITA is able now to propose operational efficacy testing service in this pathology.

Atopic Dermatitis (AD) preclinical model / Overview

Induced AD in rodents (hapten induced models / IL23-induced / oxazolone or DNCB)

Induced itching in rodents (contact dermatitis itching)

Oxazolone-induced AD preclinical model

  • Sensitization and repeated challenge with oxazolone / topically on back and ear

IL23-induced AD preclinical model

  • Repeated intradermal injection of rIL23

Itching preclinical model

  • Itching alone induction
Gravityscan Badge